These agreements significantly limi

These agreements significantly limit government ability to fulfil their population’s human right to health and life. Given the urgent need for increased access to essential patented medicines, there is no logical or patentable way to justify trading off the instrumental value of patent protection(to provide rewards and incentives for future innovation) at the present cost of the lives of millions of people. The CIPR report states this fact simply: “there are no circumstances in which the most fundamental human rights should be subordinated to the requirements of [IP] protection”. In any compulsory licensing and parallel importing in sub-Saharan Africa will likely have little impact on either corporate profits or incentives to innovate, since Africa accounts for just over 1 per cent of the global market. Moreover, the disease burden in developing regions (other than HIV/AIDS) is largely ignored in the development of new drugs, as the shocking disproportion of global health R&D expenditure on wealthy country illnesses illustrates: an estimated 90 per cent is spent on conditions affecting just 10 per cent of the world’s population, with priority conditional upon ability to pay.

ผลลัพธ์ (อังกฤษ) 2:

这些协议大大限制了政府的能力履行其人口的人的健康权和生命权。为增加获得基本专利药品的迫切需要，没有任何逻辑或专利的方法来证明交易专利保护的工具性价值（提供奖励和激励未来的创新）在数百万人的生命存在的成本。实际上，这个简单的事实的报告指出：“有没有在这种情况下，人类最基本的权利要服从要求] [ IP保护”。在任何强制许可和平行于撒哈拉以南的非洲国家的进口可能会对企业利润的影响不大或激励创新，由于非洲仅占1以上的全球市场份额。此外，在发展中地区的疾病负担（除艾滋病）是在开发新的药物，在很大程度上忽略了，作为全球健康研究&D支出对富裕国家的疾病令人震惊了：不估计百分之90是花在影响10世界人口的百分之条件，优先条件的支付能力。